Evidence map›Paper›PMID 30968548›Full record

ArticleHemodialysis international. International Symposium on Home Hemodialysis2019

Human factors testing of the Quanta SC+ hemodialysis system: An innovative system for home and clinic use.

Oksana Harasemiw, Clara Day, John E Milad, James Grainger, Thomas Ferguson, Paul Komenda

Abstract read
In one paragraph

Article in Hemodialysis international. International Symposium on Home Hemodialysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Cost of the quanta SC+ hemodialysis system for self-care in the United Kingdom.Hemodialysis international. International Symposium on Home Hemodialysis · 2022
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oksana HarasemiwChronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Canada.
Clara DayDepartment of Renal Medicine, Queen Elizabeth Hospital, Birmingham, UK.
John E MiladQuanta Dialysis Technologies Ltd., Alcester, UK.
James GraingerQuanta Dialysis Technologies Ltd., Alcester, UK.
Thomas FergusonChronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Canada.
Paul KomendaChronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Canada.

Funding

Quanta Dialysis Technologies Ltd
6 · The paper itself

Abstract

introductionUptake rates of home hemodialysis are the lowest among all modality types, despite providing patients with clinical and quality of life benefits at a lower cost to providers. Currently, there is a need to develop dialysis systems that are appealing to patients while also being suitable for use across the continuum of care. The SC+ hemodialysis system was developed by Quanta Dialysis Technologies Ltd. to provide patients with a dialysis system that is small, simple to use, and powerful enough to deliver acceptable dialysis adequacy.

methodsAs part of the SC+ design validation, human factors testing was performed with 17 Healthcare Professionals (nephrology nurses and healthcare assistants) and 15 Home Users (patients and caregivers). To assess usability and safety, the human factors testing involved between 4.5 and 6 hours of training and, after a period of training decay, a subsequent test session in which participants independently performed tasks on SC+.

findingsBetween the two user groups, there were only 29 errors observed out of 1216 opportunities for errors, despite minimal training. Errors that did occur were minor and attributed to an initial lack of familiarity with the device; none were safety related. DISCUSSION: Among prevalent dialysis patients and healthcare professionals, the SC+ hemodialysis system was easy to use, even with minimal training and a learning decay period, and had a high level of use safety. By taking into account human factors to optimize the user experience, SC+ has the potential to address systemic and patient barriers, allowing for wider self-care and home hemodialysis adoption.

Indexed as

AdultFemaleHemodialysis, HomeHumansMaleMiddle AgedQuality of LifeRenal DialysisYoung Adultend-stage renal diseaseHome hemodialysishuman factorsquality of lifeusability

Identifiers

PMID30968548
PMCPMC6850132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.